Basic Information
Enjaymo
Regulatory Information
EMEA/H/C/005776
November 15, 2022
September 15, 2022
6
April 8, 2024
Company Information
France
Tour Hekla 52 Avenue Du General De Gaulle 92800 Puteaux
RECORDATI RARE DISEASES
Drug Classification
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD).
Overview Summary
Enjaymo is a medicine for treating haemolytic anaemia (excess breakdown of red blood cells) in adults with cold agglutinin disease (CAD). CAD is a rare blood disorder where the immune system (the body’s natural defence) recognises red blood cells as foreign and attacks them. This causes agglutination (clumping together) and haemolysis (disruption) of the red blood cells, resulting in low red blood cell counts and low levels of haemoglobin. Haemolytic anaemia is rare, and Enjaymo was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 17 February 2016. Enjaymo contains the active substance sutimlimab